Biosimilar keytruda challenger enters late-stage lung cancer trial
NCT ID NCT07162883
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests whether a new drug called QL2107 works as well as the standard immunotherapy Keytruda (pembrolizumab) for people with non-small cell lung cancer that has been surgically removed. About 122 adults with stage II or IIIA lung cancer will receive either QL2107 or Keytruda after completing chemotherapy. The main goal is to see if the body processes both drugs similarly, which could lead to a more affordable treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.